PLX-MS Shows Potential Benefit in Prevention of MS <:3

A board to discuss future MS therapies in early stage (Phase I or II) trials.

PLX-MS Shows Potential Benefit in Prevention of MS <:3

Postby rainer » Mon Aug 11, 2008 9:05 pm

Pluristem's PLX-MS Shows Potential Benefit in the Prevention of Multiple Sclerosis

NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company’s PLacental eXpanded (PLX-MS) cells have demonstrated in vivo efficacy in the prevention of Multiple Sclerosis (MS). PLX cells are Pluristem’s placental-derived mesenchymal stromal cells (MSCs) that have been expanded in the Company’s proprietary PluriX™ 3-D bioreactor.

In a further analysis aiming to demonstrate the in vivo efficacy of PLX-MS cells for the prevention of MS, Experimental Autoimmune Encephalitis (EAE) was induced in mice via immunization with the MOG35-55 protein on day 0. EAE is an autoimmune inflammatory disease of the CNS that represents the paradigmatic model for MS. The animals then received, on day 8, intravenously either PLX-MS or PlasmaLyte, which served as a control. PLX-MS administration prevented the appearance of clinical symptoms and signs associated with MS throughout the 35-day study period compared to those animals receiving the control. Additionally, the beneficial effects were similar to when Zappia et. al. used MSCs that were non-placental in origin in this EAE animal model†.

Mr. Zami Aberman, Pluristem’s President and CEO, commented: “This trial’s remarkable results demonstrated our PLX-MS cells’ ability to prevent the appearance of multiple sclerosis symptoms and showed the potential for our PLX cells to treat global autoimmune diseases. As a cellular therapy, our PLX cells, which are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source, and stored ready-to-use, could prove to be a readily available preventive therapeutic alternative for these disorders."

Pluristem is initiating repeated sets of EAE experiments at the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) at Charité - University Medicine Berlin, one of the largest independent clinical research centers in Europe.

†Zappia et. al. Mesenchymal stem cells ameliorate experimental autoimmune encephalitis inducing T cell anergy. Blood. 2005;106: 1755-1761
User avatar
rainer
Family Elder
 
Posts: 367
Joined: Thu Jan 17, 2008 4:00 pm

Postby jakobm » Tue Aug 12, 2008 9:21 am

But through what mechanism do these stromal cells halt the development of MS?
User avatar
jakobm
Newbie
 
Posts: 1
Joined: Mon Aug 11, 2008 3:00 pm

Postby gwa » Tue Aug 12, 2008 10:17 am

This is a 35 day study using rats, so I am underwhelmed with these results.

gwa
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 4:00 pm

Postby rainer » Tue Aug 12, 2008 6:48 pm

I posted my mouse face icon to warn you :)

This is from the press release:

These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
User avatar
rainer
Family Elder
 
Posts: 367
Joined: Thu Jan 17, 2008 4:00 pm

Postby gwa » Tue Aug 12, 2008 6:51 pm

rainer wrote:I posted my mouse face icon to warn you :)



Cute! I see the mouse icon and will look out for it.

gwa
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 4:00 pm

Re: PLX-MS Shows Potential Benefit in Prevention of MS <:3

Postby khehran » Tue Jul 31, 2012 4:50 pm

I was horrified, when I read this study was only 35 days long! This is not good science, and many factors which are labelled as EAE in mice may not have arisen during this short time period. This is an example of how studies are manipulated in order to satisfy the needs of drug companies, in order to sell scams to innocent MS patients. You should be ashamed!!! :sad:
User avatar
khehran
Newbie
 
Posts: 9
Joined: Tue Mar 29, 2005 3:00 pm


Return to Drug Pipeline

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service